ANZCHOG Children’s Cancer Clinical Trials Repository

Study Title
ARRAY-162-115: A Multicenter, Open-label Phase 1b Study of the Combination of Binimetinib and Encorafenib in Adolescent Patients with Unresectable or Metastatic BRAF V600-mutant Melanoma
Protocol ID
ARRAY-162-115
Condition/s
Melanoma
Diagnosis Stage
New diagnosis
Relapse/refractory
Sponsor
Pfizer
Collaborators
Pierre Fabre Laboratories
Links
External Registry ≫
Trial Status
Closed to Recruitment
Study Type
Treatment
Phase
Phase 1
Age Eligibility
12 Years to 17 Years
International registry ID's
NCT03878719
Back to Registry
Study Title ARRAY-162-115: A Multicenter Open-label Phase 1b Study of the Combination of Binimetinib and Encorafenib in Adolescent Patients with Unresectable or Metastatic BRAF V600-mutant Melanoma
Protocol ID ARRAY-162-115
Disease (Sub Disease) Melanoma
Diagnosis Stage New diagnosis
Relapse/refractory
Sponsor Pfizer
Collaborators Pierre Fabre Laboratories
Links https://clinicaltrials.gov/ct2/show/NCT03878719
Trial Status Closed to Recruitment
Trial Open Date 13/08/2020
Study Type Treatment
Phase Phase 1
Age Eligibility 12 Years to 17 Years
International registry ID's NCT03878719

Join our newsletter

"*" indicates required fields

This field is for validation purposes and should be left unchanged.

Email info@anzchog.org   |  

Level 6, TRF Building, Hudson Institute, 27-31 Wright St, Clayton VIC 3168

ANZCHOG acknowledges Traditional Owners of Country throughout Australia and recognises the continuing connection to lands, waters and communities. We pay our respect to Aboriginal and Torres Strait Islander cultures, and to Elders both past and present. We acknowledge Māori as tangata whenua of Aotearoa New Zealand and as Treaty partners with the Crown as agreed in Te Tiriti o Waitangi. 

We are committed to creating a safe and welcoming environment that embraces all backgrounds, cultures, sexualities, genders and abilities.